Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) …
WEBSep 16, 2024 · – TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change ...
Buy Rating on Ascendis Pharma as TransCon CNP ... - Markets …
WEB6 days ago · Lebovitz’s optimism is also based on the drug’s weekly dosage profile, which could significantly lessen the treatment burden compared to daily injections, positioning TransCon CNP as a leading ...
Ascendis Pharma Receives Buy Rating Amid Positive Phase 3 …
WEBSep 16, 2024 · Ascendis Pharma announces data from ApproaCH trial of TransCon CNP; Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
Once-weekly TransCon CNP (navepegritide) in children with ...
WEBJul 7, 2023 · This phase 2 trial suggests that TransCon CNP is effective, safe, with low injection site reaction frequency, and may provide a novel, once-weekly treatment option for children with achondroplasia. These results support TransCon CNP at 100 μg CNP/kg/week in the ongoing pivotal trial.
Once-Weekly TransCon™ CNP Achieved Primary Efficacy …
WEBNov 13, 2022 · TransCon CNP is an investigational long-acting prodrug of C-type natriuretic peptide (CNP), designed to provide continuous exposure of CNP at safe, therapeutic levels via a single, weekly subcutaneous dose.
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide
WEBSep 16, 2024 · In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity (AGV) superior to placebo. TransCon CNP also demonstrated statistically significant improvements in other growth parameters, including height Z-score and change from baseline AGV.
Data from Phase 2 ACcomplisH Trial of TransCon CNP in
WEBCOPENHAGEN, Denmark, June 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the oral presentation of data from its Phase 2 ACcomplisH Trial of TransCon CNP...
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children …
WEBJun 24, 2024 · Patients were randomized 3:1 to receive TransCon CNP across 4 dose-escalation cohorts or placebo for 52 weeks, after which participants could receive TransCon CNP in an ongoing open-label...
Once-Weekly TransCon™ CNP Achieved Primary Efficacy …
WEBNov 16, 2023 · In the trial, patients dosed with TransCon CNP at the 100 μg CNP/kg/week showed significantly higher annualized growth velocity (AGV) than placebo (1.180 cm/year, P=0.018) at Week 52.
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To …
WEB6 days ago · In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity (AGV) superior to placebo. BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) stock is trading lower ...